Form 4: Haemonetics EVP, Chief Technology Officer Anila Lingamneni Reports Stock Sales

Anila Lingamneni, EVP and Chief Technology Officer of Haemonetics Corp, reported the sale of company stock on July 11 and 12, 2024, according to a Form 4 filing with the SEC.

Summary

• Anila Lingamneni, the EVP and Chief Technology Officer of Haemonetics Corp, filed a Form 4 with the SEC.
• The filing reports the sale of Haemonetics Corp common stock on July 11 and July 12, 2024.
• On July 11, 2024, 2,136 shares were sold at a price of $90 per share.
• On July 12, 2024, 79 shares were sold at a price of $90 per share.
• Following these transactions, Ms. Lingamneni beneficially owns 21,331 shares of Haemonetics Corp common stock, which includes unvested restricted stock units.
• The sales were executed pursuant to an existing 10b5-1 trading plan dated March 13, 2024.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing reporting stock sales by an executive. The sales were conducted under a pre-existing 10b5-1 trading plan, suggesting a neutral sentiment as these transactions are often pre-planned for personal financial management rather than reflecting a change in the executive's outlook on the company.

Industry Context

Form 4 filings are a routine part of the financial markets, providing transparency into the transactions of company insiders. Investors often monitor these filings to gain insights into management's perspective on the company's stock and future prospects.

Stakeholder Impact

• The stock sales by a company executive could have a minor impact on shareholder sentiment, although the existence of a 10b5-1 plan mitigates concerns about insider information driving the transactions.

Key Dates